Bayer Pharma AG has a total of 4,993 patent applications. It decreased the IP activity by 51.0%. Its first patent ever was published in 1994. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are GLAXOSMITHKLINE IP NO 2 LTD, TREVENA INC and KISSEI PHARMACEUTICAL CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 578 | |
#2 | EPO (European Patent Office) | 495 | |
#3 | United States | 400 | |
#4 | Canada | 333 | |
#5 | China | 324 | |
#6 | Taiwan | 191 | |
#7 | Israel | 185 | |
#8 | Republic of Korea | 174 | |
#9 | Mexico | 149 | |
#10 | Hong Kong | 140 | |
#11 | Uruguay | 139 | |
#12 | Singapore | 138 | |
#13 | Australia | 135 | |
#14 | Argentina | 134 | |
#15 | Chile | 126 | |
#16 | Brazil | 117 | |
#17 | Peru | 104 | |
#18 | Philippines | 101 | |
#19 | Tunisia | 83 | |
#20 | Costa Rica | 80 | |
#21 | Cuba | 76 | |
#22 | Dominican Republic | 72 | |
#23 | African Regional Industrial Property Organization | 70 | |
#24 | Colombia | 68 | |
#25 | Morocco | 61 | |
#26 | EAPO (Eurasian Patent Organization) | 50 | |
#27 | South Africa | 49 | |
#28 | Hungary | 46 | |
#29 | Serbia | 43 | |
#30 | Ecuador | 40 | |
#31 | Nicaragua | 40 | |
#32 | Ukraine | 37 | |
#33 | Jordan | 36 | |
#34 | Germany | 31 | |
#35 | El Salvador | 30 | |
#36 | Japan | 28 | |
#37 | New Zealand | 26 | |
#38 | Guatemala | 11 | |
#39 | India | 10 | |
#40 | Montenegro | 9 | |
#41 | Slovenia | 9 | |
#42 | Croatia | 7 | |
#43 | Georgia | 6 | |
#44 | Norway | 4 | |
#45 | Honduras | 3 | |
#46 | Malaysia | 2 | |
#47 | Bulgaria | 1 | |
#48 | Egypt | 1 | |
#49 | Russian Federation | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Measurement |
# | Name | Total Patents |
---|---|---|
#1 | Lienau Philip | 580 |
#2 | Siemeister Gerhard | 492 |
#3 | Wunder Frank | 347 |
#4 | Vakalopoulos Alexandros | 286 |
#5 | Stasch Johannes-Peter | 283 |
#6 | Tersteegen Adrian | 274 |
#7 | Follmann Markus | 258 |
#8 | Lang Dieter | 252 |
#9 | Briem Hans | 249 |
#10 | Redlich Gorden | 231 |
Publication | Filing date | Title |
---|---|---|
WO2021013693A1 | Antibody drug conjugates (adcs) with nampt inhibitors | |
WO2020094471A1 | Cytostatic conjugates with integrin ligands | |
WO2020048828A1 | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds | |
EP3781565A1 | 2-methyl-aza-quinazolines | |
PE20210165A1 | A SUBSTITUTED OXOPYRIDINE DERIVATIVE | |
US2019307728A1 | Methods of treatment with a 2,4,5-trisubstituted 1,2,4-triazolone | |
EP3774769A1 | 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders | |
WO2019180072A1 | Parenteral pharmaceutical composition comprising neladenoson bialanate | |
US2019240231A1 | Reducing the risk of cardiovascular events | |
US2019177279A1 | Carboxylic acid aromatic 1,2-cyclopropylamides | |
US2019177284A1 | Tetrazolyl-containing cyclopropanecarboxamides | |
US2019194148A1 | Tetrazole-containing 1,2-cyclopropane-carboxamides | |
CN111433204A | Process for the preparation of (3S) -3- (4-chloro-3- { [ (2S,3R) -2- (4-chlorophenyl) -4,4, 4-trifluoro-3-methylbutyryl ] amino } phenyl) -3-cyclopropylpropionic acid and crystalline forms thereof for use as a pharmaceutically active substance | |
CA3084755A1 | Process for preparing benzothiophen-2yl boronate | |
US2020253961A1 | Amine substituted triazole derivatives and uses thereof | |
EP3700898A1 | Substituted triazole derivatives and uses thereof | |
EP3700897A1 | Substituted triazole derivatives and uses thereof | |
EP3700899A1 | Substituted triazole derivatives and uses thereof | |
TW201919636A | Formulations of COPANLISIB | |
WO2019038156A1 | Use of an ep4 antagonist for the treatment of arthritis |